YEZTUGO in Long Island City

Planning Yeztugo care near your chosen location

Ask the chosen location whether it can arrange the prescribed tablets and professional subcutaneous injections, review HIV tests and coordinate future visits. Bring prior PrEP/PEP dates and discuss travel between locations or states before starting. Confirm which clinician receives pending RNA and confirmatory results and manages interruptions. A convenient neighborhood is useful only if the supply and follow-up pathway fits your plan. A published address does not verify stock, an injection slot or plan approval. If you need another site, get a coordinated referral and preserve prevention while the move is arranged.

Yeztugo twice-yearly HIV PrEP

Yeztugo is lenacapavir for prevention of sexually acquired HIV-1 in people who do not have HIV. Treatment starts with injections and tablets, then continues with injections about every six months. It can suit someone who prefers fewer medication visits, provided testing and follow-up remain reliable. Twice-yearly medication does not mean twice-yearly attention to every health concern: a new exposure, symptoms, STI screening or a medication change can require contact sooner.

How Yeztugo twice-yearly HIV PrEP works

Lenacapavir blocks several stages of HIV replication by acting on the viral capsid. Yeztugo is the prevention product. Sunlenca contains the same active medicine but is used with other antiretrovirals for selected people with HIV whose prior treatments have not worked. The brands and care pathways are not interchangeable. Yeztugo alone must not be used as HIV treatment.

Eligibility: Yeztugo twice-yearly HIV PrEP

The approved PrEP indication is for adults and adolescents weighing at least 35 kg who are at risk of acquiring HIV through sex. HIV-negative status must be established. Recent exposure, acute viral symptoms, past PrEP/PEP, pregnancy or breastfeeding and all current medicines belong in the evaluation. HIV testing is required before starting and before each injection. A positive or unknown HIV status prevents use as PrEP.

What to expect: Yeztugo twice-yearly HIV PrEP

Confirm HIV status and exposure timing

At initiation, a negative antigen/antibody test is confirmed with HIV RNA testing, even if RNA returns after treatment starts. Before continuation, a negative rapid antigen/antibody test requires confirmation with a more sensitive assay. The clinician determines the complete testing approach and reviews symptoms and any ambiguous results.

Review medicines and practical access

Provide every prescription, over-the-counter medicine and supplement. Some strong or moderate CYP3A inducers require additional clinician-directed dosing under the August 2026 label; other starting combinations have no recommended regimen. Your prescriber must review the actual medicines and sequence.

Complete initiation

The labeled start includes two subcutaneous injections and oral tablets on the first day, followed by oral tablets the next day. Those tablets are part of required initiation, not an optional tolerability trial. A trained professional administers the injections.

Book continuing prevention care

Continuation injections are scheduled every 26 weeks with a two-week allowance on either side. Agree on HIV testing, STI screening and what to do before travel or an access delay.

Preparing for your appointment

Bring previous HIV and STI results, your current prevention regimen, last injection date if applicable and insurance information. Ask how the next-day tablets will be obtained and how to contact the team if you cannot take them. Confirm medication receipt and testing arrangements before an administration visit. The label describes abdominal injections and an alternative thigh site; the administrator chooses an appropriate site using the current instructions.

Risks and when to seek help

The boxed warning concerns resistance if Yeztugo is used during undetected HIV. Report possible acute HIV symptoms immediately rather than waiting for a routine dose. Injection pain, swelling or nodules can occur; some nodules last a long time. Seek urgent care for severe allergic symptoms or a rapidly worsening injection-site reaction. Lenacapavir can affect other medicines long after the last injection, so tell future prescribers when you received it.

Follow-up and treatment review

Call before an injection is overdue. An authorized oral bridge may be used for some planned delays, but the tablets are not a patient-designed substitute for injections. Longer gaps without bridging can require repeating initiation after reassessment. After stopping, residual drug may remain for 12 months or longer. Your clinician plans ongoing HIV testing and alternative prevention while levels decline.

Appointments, costs and coverage

Ask separately about tablet coverage, injectable medication coverage, laboratory testing and administration charges. The supply may require authorization and shipment to an administration site. Assistance programs have eligibility rules and do not prove that a particular clinic or insurer participates. Keep a written transition plan while these steps are completed; confirm actual availability before traveling to a listed location.

Booking and visit preparation

Nao Medical Long Island City: 30-07 36th Ave, Long Island City, NY 11106. Call +1-917-310-3371 to confirm the specific service, clinician and appointment before travelling.

Clinic information

Contact the clinic to confirm this service, the clinician and appointment preparation. General clinic hours may differ from service appointment times.

Medical sources

• Yeztugo US prescribing information
• NIH lenacapavir patient drug record
• CDC injectable lenacapavir PrEP recommendation
• Gilead investigational once-yearly lenacapavir status
• Gilead weekly oral lenacapavir application status
• CDC HIV testing
• CDC PEP clinical guidance
• CDC clinical guidance for PrEP